- Home
- PCSA vs PRFX Comparison
PCSA vs PRFX Comparison
Compare PCSA & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- PRFX
- Stock Information
- Founded
- PCSA 2011
- PRFX 2007
- Country
- PCSA United States
- PRFX Israel
- Employees
- PCSA N/A
- PRFX N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- PCSA Health Care
- PRFX Health Care
- Exchange
- PCSA Nasdaq
- PRFX Nasdaq
- Market Cap
- PCSA 3.3M
- PRFX 2.8M
- IPO Year
- PCSA N/A
- PRFX 2020
- Fundamental
- Price
- PCSA $0.24
- PRFX $1.49
- Analyst Decision
- PCSA Strong Buy
- PRFX Hold
- Analyst Count
- PCSA 1
- PRFX 1
- Target Price
- PCSA $2.00
- PRFX N/A
- AVG Volume (30 Days)
- PCSA 8.3M
- PRFX 256.2K
- Earning Date
- PCSA 08-12-2025
- PRFX 08-14-2025
- Dividend Yield
- PCSA N/A
- PRFX N/A
- EPS Growth
- PCSA N/A
- PRFX N/A
- EPS
- PCSA N/A
- PRFX N/A
- Revenue
- PCSA N/A
- PRFX N/A
- Revenue This Year
- PCSA N/A
- PRFX N/A
- Revenue Next Year
- PCSA N/A
- PRFX N/A
- P/E Ratio
- PCSA N/A
- PRFX N/A
- Revenue Growth
- PCSA N/A
- PRFX N/A
- 52 Week Low
- PCSA $0.15
- PRFX $1.25
- 52 Week High
- PCSA $3.10
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- PCSA 51.45
- PRFX 46.04
- Support Level
- PCSA $0.21
- PRFX $1.44
- Resistance Level
- PCSA $0.26
- PRFX $1.55
- Average True Range (ATR)
- PCSA 0.03
- PRFX 0.10
- MACD
- PCSA 0.01
- PRFX 0.03
- Stochastic Oscillator
- PCSA 55.70
- PRFX 61.54
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.